The Relative Strength (RS) Rating for Protagonist Therapeutics moved up into a higher percentile Thursday, as it got a lift from 70 to 73.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best stocks often have an 80 or higher RS Rating as they begin their largest climbs. See if Protagonist Therapeutics can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Protagonist Therapeutics is trying to complete a consolidation with a 48.89 buy point. See if it can break out in heavy trade.
Protagonist Therapeutics showed 0% EPS growth in its most recent report. Sales increased -100%. Look for the next report on or around Mar. 18.
Protagonist Therapeutics earns the No. 17 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Jazz Pharmaceuticals and Novartis ADR are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
